The liver plays an important physiological role in lipopolysaccharide (LPS) detoxification and, in particular, hepatocytes are involved in the clearance of endotoxin of intestinal derivation. In experimental shock models, tumor necrosis factor (TNF)-α induces hepatocyte apoptosis and lethal effects are due to secreted TNF-α and not to cell-associated TNF-α. An exaggerated production of TNF-α has been reported in murine viral infections, in which mice become sensitized to low amounts of LPS and both interferon (IFN)-γ and IFN-α/β are involved in the macrophage-induced release of TNF-α. The prominent role of LPS and TNF-α in liver injury is also supported by studies of ethanol-induced hepatic damage. In humans, evidence of LPS-induced hepatic injury has been reported in cirrhosis, autoimmune hepatitis, and primary biliary cirrhosis and a decreased phagocytic activity of the reticulo-endothelial system has been found in these diseases. The origin of endotoxemia in hepatitis C virus (HCV) infected patients seems to be multifactorial and LPS may be of exogenous or endogenous derivation. In endotoxemic HCV-positive patients responsive to a combined treatment with IFN-α/ribavirin (RIB), endotoxemia was no longer detected at the end of the therapeutic regimen. By contrast, 48% of the non-responders to this treatment were still endotoxemic and their monocytes displayed higher intracellular TNF-α and interleukin (IL)-1β levels than responders. Moreover, in responders, an equilibrium between IFN-γ and IL-10 serum levels was attained. In the non-responders, serum levels of IL-10 did not increase following treatment. This may imply that an imbalance between T helper (Th)1 and Th2 derived cytokines could be envisaged in the non-responders.
References
1.
Fox ES, Thomas P., Broitmans A.Clearance of gut-derived endotoxins by the liver. Release and modifications of 3H,14C-lipopolysaccharide by isolated Kupffer cells. Gastroenterology1989; 96: 456—461.
2.
Liu S., Khemlani LS, Shapiro RA et al. Expression of CD14 by hepatocytes: upregulationby cytokines during endotoxemia. Infect Immun1998; 66: 5089—5098.
3.
Fearns C., Kravchenko VV, Ulevitch RJ et al. MurineCD14 gene expression in vivo: extramyeloid synthesis and regulation by lipopolysaccharides. J Exp Med1995; 181: 857—866.
4.
Knolle PA, Limmer A.Neighborhood politics: the immunoregulatory function of organ-resident liver endothelial cells. Trends Immunol2001 ; 22: 432—437.
5.
Rehermann B.Immunopathogenesis of viral hepatitis. Baillière'sClin Gastroenterol1996; 10: 483—500.
6.
Cella M., SallustoF, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol1997 ; 9: 10—15.
7.
Opal SM, Scannon PJ, Vincent J-L. et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis1999; 180: 1584—1589.
8.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JCCD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science1990; 249: 1431—1433.
9.
PoltorakA.,HeX., Smirnova I. et al. Defective LPS signaling in C3H/HeJ and C57BL/l OScCr mice: mutations in TLR4 gene. Science1998; 282: 2085—2088.
10.
Ruiter DJ, van der Meulen J., Brouwer A. et al. Uptake by liver cells of endotoxin following its intravenous injection. Lab Invest1981; 45: 38—45.
11.
Freudenberg MA, Galanos C.Bacterial lipopolysaccharides: structure, metabolism and mechanisms of action. Int Rev Immunol1990; 6: 207—221.
12.
Maitra SK, Rachmilewitz D., Eberle D. et al. The hepatocellular uptake and biliary excretion of endotoxin in the rat. Hepatology1981; 8: 1550—1554.
13.
Jackson GD, Dai Y., Sewell WABile mediates intestinal pathology in endotoxemia in rats. Infect Immun2000; 68: 4714—4719.
14.
Zlydaszyk JC , Moon RJFate of 51Cr-labeled lipopolysaccharide in tissue culture cells and livers of normal mice. Infect Immun1976; 14: 100—105.
15.
Mimura Y., Sakisaka S., Harada M. et al. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology1995; 109: 1969—1976.
16.
Vodovotz Y., Liu S., McCloskey C., Shapiro S. et al. The hepatocyte as a microbial product-responsive cell. J Endotoxin Res2001; 7: 365—373.
17.
Means TK, Golenbock DT, Fenton MJThe biology of Toll-like receptor. Cytokine Growth Factor Rev2000: 11; 219—232.
18.
van Oosten M. , van Amersfoort ES, van Berkel Tjc et al. Scavenger receptor-like receptors for the binding of lipopolysaccharide and lipoteichoic acid to liver endothelial and Kupffer cells. J Endotoxin Res2001; 7: 381—384.
19.
Ingalls RR, GolenbockDT. CD11c/CD18, a transmembrane signaling receptor for lipopolysaccharide . J Exp Med1995; 181: 1473—1479.
20.
Parent JBMembrane receptors on rat hepatocytes for the inner core region of bacterial lipopolysaccharide. J Biol Chem1990; 265: 3455—3461.
21.
Galanos C., Freudenberg MA, Reutter W.Galactosamine-induced sensitization to the lethal effects of endotoxin . Proc Natl Acad Sci USA1979; 76: 5939—5943.
22.
Mignon A., Rouquet N., Fabre M. et al. LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med1999; 159: 1308—1315.
23.
Leist M., Gantner F., Jilg S., Wendel A.Activation of the 55 kDa TNF receptor is necessary and sufficient for TNF-induced liver failure, hepatocyte apoptosis, and nitrite release. J Immunol1995; 154: 1307—1316.
24.
Jaeschke H. , Fisher MA, Lawson JA, Simmons CA, Farhood A., Jones DAActivation of caspase 3 (CPP32)-likeproteases is essential for TNF-α-induced hepatic parenchymal cell apoptosis and neutrophilmediated necrosis in a murine endotoxin shock model. J Immunol1998; 160: 3480—3486.
25.
Oberholzer A., Oberholzer C., Bahjat FR, Edwards 3rd CK, Moldawer LLGenetic determinants of lipopolysaccharide and D-galactosamine-mediated hepatocellular apoptosis and lethality. J Endotoxin Res2001; 7: 375—380.
26.
BahjatFR, Dharnidharka VR, FukuzukaK., Morel L., Clare-Salzler M., Moldawer LLReduced susceptibility of NOD mice to tumor necrosis factor and D-galactosamine-mediated hepato-cellular apoptosis and lethality. J Immunol2000; 165: 6559—6567.
27.
Tannahil CL , Fukuzuka K., Marum T. et al. Discordant tumor necrosis factor-alpha superfamily gene expression in bacterial peritonitis and endotoxemic shock . Surgery1999; 126: 349—357.
28.
Kondo T., Suda T., Fukuyama H., Adachi M., Nagata S.Essential roles of the Fas ligand in the development of hepatitis . Nat Med1997; 3: 409—413.
29.
Tsutsui H., Matsui K., Okamura H., Nakanishi K.Pathophysiological roles of interleukin-18 in inflammatory liver diseases . Immunol Rev2000; 174: 192—209.
30.
Li XK, Fujino M., Sugioka A. et al. Fulminanthepatitis by Fas-ligand expression in MRL-lpr/lpr mice grafted with Fas-positive livers and wild-type mice with Fas-mutant livers . Transplantation2001; 71: 503—507.
31.
Vento S.Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. J Viral Hepat2000 ; 7: 7—8.
32.
Nguyen KB, Biron CASynergism for cytokine-mediated disease during concurrent endotoxin and viral challenges: roles for NK and T cell IFN-gamma production. J Immunol1999; 162: 5238—5246.
33.
Nansen A., Thomsen ARViral infection causes rapid sensitization to lipopolysaccharide: central role of IFN-alpha beta. J Immunol2001; 166: 982—988.
34.
Belardelli F., Gresser I.The neglected role of type I interferon in the T-cell response: implication and clinical use. Immunol Today1996; 17: 369—372.
35.
Weinstock-Guttman B., Ransohoff RM, Kinkel RP, Rudick RAThe interferons: biological effects, mechanisms of action and use in multiple sclerosis. Ann Neurol1995; 37: 7—15.
36.
van Molle W. , Denecker G., Rodriguez I., Brouckaert P., Vandenabeele P., Libert C.Activation of caspases in lethal experimental hepatitis and prevention by acute phase proteins . J Immunol1999; 163: 5235—5241.
37.
Enomoto N., Ikejima K., Bradford BU et al. Alcohol causes both tolerance and sensitization of rat Kupffer cells via mechanisms dependent on endotoxin. Gastroenterology1998; 115: 443—451.
38.
Adachi Y., Moore LE, Bradford BU, Gao W., Bojes HK, Thurman RGAntibiotics prevent liver injury in rats following long-term exposure to ethanol . Gastroenterology1995; 108: 218—224.
Iimuro Y., Gallucci RM, Luster MI, Kono H., Thurman RGAntibodies to tumor necrosis factor-alpha attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology1997; 26: 1530—1537.
41.
Yin M., Wheeler MD, Kono H. et al. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury. Gastroenterology1999; 117: 942—952.
42.
Adachi Y., Bradford BU, Gao W., Bojes HK, Thurman RGInactivation of Kupffer cells prevents early alcohol-induced liver injury . Hepatology1994; 20: 453—460.
43.
Yin M., Bradford BU, Wheeler MD et al. Reduced early alcoholinduced liver injury in CD14-deficient mice. J Immunol2001; 166: 4737—4742.
44.
Dieleman LA , Arends A., Tonkonogy SL et al. Helicobacter hepaticus does not induce or potentiate colitis in interleukin-10-deficient mice. Infect Immun2000; 68: 5107—5113.
45.
Shomer NH, Dangler CA, Schrenzel MD, Fox JGHelicobacter bilisinduced inflammatory bowel disease in SCID mice with defined flora. Infect Immun1997; 65: 4858—4864.
46.
Spitzer JJ, Mèszàros K., B autista AP, Lang CH, Spolarics Z.Potential contribution of phagocytic cells to liver damage after Escherichia coli endotoxin. In: Nowotny A, Spitzer JJ, Ziegler EJ. (eds) Cellular and Molecular Aspects of Endotoxin Reactions. Amsterdam: Elsevier, 1990;521-528.
47.
Secchi A., Ortanderl JM, Schmidt W., Gebhard MM, Martin E., Schmidt H.Effect of endotoxemia on hepatic portal and sinusoidal blood flow in rats . J Surg Res2000; 89: 26—30.
48.
Novitsky TJLimulus amebocyte lysate (LAL) detection of endotoxin in human blood. J Endotoxin Res1994; 1: 253—263.
49.
Roslanky PF , Novitsky TJSensitivity of Limulus amebocyte lysate (LAL) to LAL reactive glucans. J Clin Microbiol1991; 29: 2477—2483.
50.
Nolan JPThe role of endotoxin in liver injury. Gastroenterology1975; 69: 1345—1356.
51.
Liehr H., Grun M., Brunswig D., Sautter T.Endotoxinamiebei Leberzirrhose. Z Gastroenterol1976; 14: 14—23.
52.
Prytz H., Holtz-Christensen J., Korner B., Liehr H.Portal venous and systemic endotoxaemia in patients without liver disease and systemic endotoxaemia in patients with cirrhosis. Scand J Gastroenterol1976; 11: 857—863.
53.
Chan CC, Hwang SJ, Lee FY et al. Prognostic value of plasma endotoxin levels in patients with cirrhosis . Scand J Gastroenterol1997; 32: 942—946.
54.
Kuratsune H. , Koda T., Kurahori T.The relationship between endotoxin and the phagocytic activity of the reticuloendothelial system. Hepatogastroenterology1983; 30: 79—82.
55.
Ueno M.Endotoxemia and its compensatory mechanisms in experimental liver cirrhosis . Nippon Shokakibyo Gakkai Zasshi1990; 87: 1692—1700.
56.
Sato T., Asanuma Y., Tanaka J., Koyama K.Inflammatory cytokine production enhancement in the presence of lipopolysaccharide after hepatic resection in cirrhotic patients. Ther Apher1997; 1: 75—78.
57.
Stemerowicz R. , Moller B., Martin P. et al. Antibody activity against lipopolysaccharides, lipid A and proteins from Enterobacteriaceae in patients with chronic inflammatory liver diseases. Autoimmunity1990; 7: 305—315.
58.
Hopf U., Moller B., Stemerowicz R. et al. Relation between Escherichia coli R (rough)-form in gut, lipid A in liver, and primary biliary cirrhosis. Lancet1989; 2: 1419—1422.
59.
Jirillo E., Amati L., Caradonna L. et al. Soluble (s) CD14 and plasmatic lipopolysaccharides (LPS) in patients with chronic hepatitis C before and after treatment with interferon (IFN)-α. Immunopharmacol Immunotoxicol1998; 20: 1—14.
60.
Oesterreicher C., Pfeffel F., Petermann D., Muller C.Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol1995; 23: 396—402.
61.
Praaning-van Dalen DP, Brouwer NA, Knook DLClearance capacity of rat liver Kupffer, endothelial, and parenchymal cells. Gastroenterology1981 ; 81: 1036—1044.
62.
Chensue SW, Terebuh PD, Remick DG, Scales WE, Kunkel SLIn vivo biologic and immunohistochemical analysis of interleukin-1 alpha, beta and tumor necrosis factor during experimental endotoxemia. Kinetics, Kupffer cell expression, and glucocorticoid effects. Am J Pathol1991; 1338: 395—402.
63.
Knolle PA, Loser E., Protzer V. et al. Regulation of endotoxin-induced IL-6 production in liver sinusoidal endothelial cells and Kupffer cells by IL-10. Clin Exp Immunol1997; 107: 555—561.
64.
Jirillo E., Greco B., Caradonna L. et al. Evaluation of cellular immune responses and soluble mediators in patients with chronic hepatitis C virus (cHCV) infection. Immunopharmacol Immunotoxicol1995; 17: 347—364.
65.
Jirillo E., Greco B., Caradonna L. et al. Immunological effects following administration of interferon-α in patients with chronic hepatitis C virus infection. Immunopharmacol Immunotoxicol1996; 18: 355—374.
66.
Jirillo E., Pellegrino NM, Piazzolla G., Caccavo D., Antonaci S.Hepatitis C virus infection: immune responsiveness and interferon-α treatment . Curr Pharm Design2000; 6: 169—180.
67.
Li L., Wu Z., Ma W., Yu Y., Chen Y.Changes in intestinal microflora in patients with chronic severe hepatitis . Chin Med J2001; 114: 869—872.
68.
Caradonna L. , Mastronardi ML, Magrone T. et al. Biological and clinical significance of endotoxemia in the course of hepatitis C virus infection . Curr Pharm Design2002; 8: 945—1005.
69.
Caccavo D., Afeltra A., Pece S. et al. Lactoferrin-lipid A-lipopolysaccharide interaction: inhibition by anti-human lactoferrin monoclonal antibody AGM 10.14. Infect Immun1999; 67: 4668—4672.
70.
Ikeda M., Nozaki A., Sugiyama K. et al. Characterization of antiviral activity of lactoferrin against hepatitis C virus infection in human cultured cells. Virus Res2000; 66: 51—63.
Poynard T., Leroy V., Cohard M. et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology1996; 24: 778—789.
73.
McHutchison JG, Poynard T. . Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis1999; 19 (Suppl. 1): 57—65.
74.
Davis LGCombination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin Liver Dis1999; 19 (Suppl. 1): 49—55.
75.
Patterson JL , Fernandez-Larrson R.Molecular mechanisms of action of ribavirin. Rev Infect Dis1990 ; 12: 1139—1146.
76.
Cozzolongo R., Cuppone R., Giannuzzi V. et al. Combination therapy with ribavirin and alpha interferon for the treatment of chronic hepatitis C refractory to interferon. Aliment Pharmacol Ther2001; 15: 129—135.
77.
Amati L., CaradonnaL., Magrone T. et al. Modification of the immune responsiveness in patients with hepatitis C virus infection following treatment with IFN-α/ribavirin. Curr Pharm Design2002; 8: 981—993.
78.
Le Moine O, Marchant A., Degroote D., Azar C., Goldman M., Deviere J.Role of defective monocyte interleukin-10 release in tumor necrosis factor overproduction in alcoholics cirrhosis. Hepatology1995; 22: 1436—1439.
79.
Tian Z., Shen X., Feng H., Gao B.IL-1 beta attenuates IFN-alpha/betainduced antiviral activity and Stat1 activation in the liver: involvement of proteasome-dependent pathway. J Immunol2000; 165: 3959—3965.
80.
Durbin JE, Hackenmiller R., Simon MC, Levy DETargeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. Cell1996; 84: 443—450.
81.
Llorent L., Richaud-Patin Y., Alcocer-Castillejos N. et al. Cytokine gene expression in cirrhotic and non cirrhotic human liver. J Hepatol1996; 24: 555—563.
82.
Diehl AMCytokine and the molecular mechanisms of alcoholic liver disease. Alcohol Clin Exp Res1999; 23: 1419—1424.
83.
MatsuuraM,GalanosC. Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium . Infect Immun1990; 58: 935—937.
84.
Katschinski T., Galanos C., Coumbos A., Freudenberg MAγ-Interferon mediates Propionibacterium acnes-induced hypersensitivity to lipopolysaccharide in mice. Infect Immun1992; 60: 1994—2001.
85.
Freudenberg MA, Kopf M., Galanos C.Lipopolysaccharide-sensitivity of interferon-γ-receptor deficient mice. J Endotoxin Res1996; 3: 291—295.
86.
Trinchieri G.Interleukin-12: a cytokine at the interface of inflammation and immunity. Adv Immunol1998; 70: 243—283.
87.
Merlin T., Sing A., Nielsen PJ, Galanos C., Freudenberg MAInherited IL-12 unresponsiveness contributes to the high LPS resistance of the LPS C57BL/10ScCr mouse. J Immunol2001 ; 166: 566—573.
88.
Galanos C., Gumenscheimer M., Mühlradt PF, Jirillo E., Freudenberg MAMALP-2, a mycoplasm lipopeptidewith classical endotoxic properties: end of an era of LPS monopoly?J Endotoxin Res2000 ; 6: 471—476.
89.
Conn HO, Atterbury CECirrhosis. In: Schiff L, SchiffER. (eds) Diseases of the Liver. Philadelphia, PA: JB Lippincott, 1993; 875—934.
90.
Kodali VP, Gordon SC, Silverman AL, McCray DGCryptogenic liver disease in the United States: further evidence for non-A, non-B, and non-C hepatitis. Am J Gastroenterol1994; 89: 1836—1839.
91.
Caldwell SH , Oelsner DH, Iezzoni JC, HespenheideEE, Battle EH, Driscoll CJ. Cryptogeniccirrhosis: clinical characterization and risk factors for underlying disease. Hepatology1999; 29: 664—669.
92.
Mathiesen UL , Franzèn LE, Frydèn A., Foberg U., Bodemar G.The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. Scand J Gastroenterol1999; 34: 85—91.
93.
Skelly MM, James PD, Ryder SDFindings on liver biopsy to investigate abnormal liver function tests in the absence of diagnostic serology. J Hepatol2001; 35: 195—199.
94.
Zipfel A., Schenk M., You MS, Lauchart W., Bode C., Viebahn R.Endotoxemia in organ donors. Graft function following liver transplantation . Transpl Int2000; 13 (Suppl. 1): S286—S287.
